新辅助帕妥珠单抗、阿替利珠单抗、多西他赛和曲妥珠单抗方案治疗ERBB2阳性II/III期乳腺癌患者的缓解率与安全性:Neo-PATH 2期非随机临床试验
这项由韩国癌症研究组开展的非随机、开放标签、多中心2期试验纳入67例ERBB2阳性II/III期乳腺癌患者,给予6周期新辅助帕妥珠单抗、阿替利珠单抗、多西他赛和曲妥珠单抗治疗后手术,总体病理完全缓解(pCR)率为61%(41/67),激素受体阴性者pCR率77%(27/35)高于阳性者44%(14/32),3-4级中性粒细胞减少发生8例(12%),结论认为该方案pCR率可接受且毒性温和,值得进一步研究。
要点
- 总体pCR率为61%(41/67),激素受体阴性77%(27/35)vs阳性44%(14/32)。
- 程序性细胞死亡1阳性者pCR率100%(13/13)vs阴性者53%(28/53)。
- 3-4级中性粒细胞减少8例(12%),发热性中性粒细胞减少5例(8%)。
核心结论
- 在II/III期ERBB2阳性乳腺癌中,新辅助阿替利珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗方案似乎具有可接受的pCR率和温和的毒性反应。
- 作者认为有必要在ERBB2阳性早期乳腺癌中进一步研究该免疫治疗联合方案。
研究设计与样本
- 非随机、开放标签、多中心2期试验,由韩国癌症研究组开展,纳入韩国6家机构的患者,入组时间为2019年5月至2020年5月。
- 共纳入67例女性患者,中位年龄52岁(范围33-74岁),诊断为ERBB2阳性乳腺癌(原发肿瘤>2 cm或病理证实淋巴结阳性、无远处转移),临床分期为II或III期。
- 患者接受6周期新辅助帕妥珠单抗(首周期840 mg,后续周期420 mg)、阿替利珠单抗(1200 mg)、多西他赛(75 mg/m2)和曲妥珠单抗(600 mg皮下注射)每3周一次,随后手术。
- 达到pCR的患者术后接受12周期辅助阿替利珠单抗、曲妥珠单抗和帕妥珠单抗每3周一次;未达pCR者接受14周期阿替利珠单抗1200 mg联合曲妥珠单抗 emtansine 3.6 mg/kg每3周一次。
主要发现
- 65例患者接受了根治性手术,2例在新辅助治疗期间出现疾病进展、肿瘤变为不可切除。
- 总体pCR率为61%(41/67)。
- 激素受体阴性者pCR率为77%(27/35),激素受体阳性者为44%(14/32)。
- 程序性细胞死亡1阳性表达者pCR率为100%(13/13),阴性表达者为53%(28/53)。
- 3-4级中性粒细胞减少发生于8例(12%)患者,发热性中性粒细胞减少发生于5例(8%)患者;3-4级免疫相关不良事件仅发生于4例患者(3级皮疹、脑炎、肝炎和发热);新辅助阶段无治疗相关死亡。
关键数值与推荐
- pCR定义为原发肿瘤和区域淋巴结中无侵袭性癌细胞(ypT0/isN0)。
- 主要终点为pCR率;次要终点包括临床客观缓解率、按pCR达成情况分析的3年无事件生存率、无病生存期、总生存期、毒性反应和生活质量结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Addition of immune checkpoint inhibitors to anti-ERBB2 treatment has shown synergistic efficacy in preclinical studies and is thus worth investigating as a neoadjuvant treatment to maximize efficacy and to minimize toxic effects. OBJECTIVE: To determine if neoadjuvant atezolizumab, docetaxel, trastuzumab, and pertuzumab therapy for ERBB2-positive early breast cancer warrants continuation to the next phase. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized, open label, multicenter, phase 2 trial was conducted by the Korean Cancer Study Group and enrolled patients across 6 institutions in Korea from May 2019 to May 2020. Eligible patients were diagnosed with ERBB2-positive breast cancer (primary tumor size >2 cm or pathologically confirmed lymph node-positive cancer, without distant metastases) with a clinical stage of II or III. INTERVENTIONS: Patients received 6 cycles of neoadjuvant pertuzumab (840 mg at first cycle, 420 mg during subsequent cycles), atezolizumab (1200 mg), docetaxel (75 mg/m2), and trastuzumab (600 mg via subcutaneous injection) every 3 weeks, followed by surgery. Patients with pathologic complete response (pCR) received 12 cycles of adjuvant atezolizumab, trastuzumab, and pertuzumab every 3 weeks after surgery. Patients without pCR were treated with 14 cycles of atezolizumab, 1200 mg, plus trastuzumab emtansine, 3.6 mg/kg, every 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was pCR rate, which was defined as the absence of invasive cancer cells in the primary tumor and regional lymph nodes (ypT0/isN0). Secondary end points included clinical objective response rate, 3-year event-free survival rate according to pCR achievement, disease-free survival, overall survival, toxic effects, and quality-of-life outcomes. RESULTS: A total of 67 women (median [range] age, 52 [33-74] years) were enrolled. Hormone receptor expression was positive in 32 (48%) patients. Curative surgery was performed in 65 patients because 2 patients showed disease progression during neoadjuvant treatment and their tumors became unresectable. The overall pCR rate was 61% (41 of 67 patients). The pCR rate was higher in hormone receptor-negative disease vs hormone receptor-positive disease (27 of 35 [77%] patients vs 14 of 32 [44%] patients) and in programmed cell death 1-positive expression vs programmed cell death 1-negative expression (13 of 13 [100%] patients vs 28 of 53 [53%] patients). Grade 3 and 4 neutropenia and febrile neutropenia occurred in 8 (12%) patients and 5 (8%) patients, respectively. Grade 3 and 4 immune-related adverse events occurred in only 4 patients (grade 3 skin rash, encephalitis, hepatitis, and fever). No treatment-related death occurred during the neoadjuvant phase. CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, treatment with the neoadjuvant atezolizumab, docetaxel, trastuzumab, and pertuzumab regimen in patients with stage II or III ERBB2-positive breast cancer appears to have had an acceptable pCR rate and modest toxic effects. Further investigation of this immunotherapy combination in ERBB2-positive early breast cancer is warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03881878.
引用
- Ahn HK, Sim SH, Suh KJ, et al. Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2022. PMID: 35797012. doi:10.1001/jamaoncol.2022.2310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。